Monopar Therapeutics financials
$80.00−4.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M | -$6.5M | -$4.3M |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M | -$6.3M | -$4.2M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-1.85 | $-4.11 | $-3.04 | $-4.15 | $-3.65 | $-2.90 | $-2.25 |
| EBITDA | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M | -$6.5M | -$4.3M |
| Operating cash flow | -$12.2M | -$6.4M | -$7.9M | -$7.2M | -$7.3M | -$4.8M | -$3.0M |
| Free cash flow | -$12.2M | -$6.4M | -$7.9M | -$7.2M | — | — | — |
| Diluted shares | 7.4M | 3.8M | 2.8M | 2.5M | 2.5M | 2.2M | 1.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M | $16.7M |
| Short-term investments | $78.6M | $14.4M | $0.00 | $4.9M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M | $16.9M |
| Total liabilities | $2.9M | $5.3M | $1.8M | $3.1M | $1.6M | $1.2M |
| Shareholders' equity | $137.8M | $55.0M | $5.6M | $10.1M | $18.9M | $15.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology